Jupiter Neurosciences, Inc. (JUNS)

Jupiter Neurosciences, Inc. (JUNS) Healthcare & Pipeline Overview

Jupiter Neurosciences, Inc. is a clinical-stage biotechnology company specializing in the development of resveratrol-based treatments for neuro-inflammation. With a focus on rare diseases and neurological conditions, the company has several Phase II trials underway, positioning it within the high-risk, high-reward pharmaceutical landscape.

What Is the Investment Thesis for JUNS?

Jupiter Neurosciences presents a high-risk, high-reward investment opportunity characteristic of clinical-stage biotechnology companies. The company's focus on neuro-inflammation and rare diseases offers the potential for significant returns if its Phase II trials yield positive results. Key value drivers include the successful advancement of JNS101 for Friedreich's Ataxia and JNS102 for mucopolysaccharidosis Type I through clinical trials and eventual FDA approval. The company's small size and focused approach could also make it an attractive acquisition target for larger pharmaceutical companies. However, the company's negative profit margin of -39662.8% underscores the significant financial risks associated with drug development, and the company's future is highly dependent on clinical trial outcomes and regulatory approvals.

Based on FMP financials and quantitative analysis

JUNS Key Highlights

• Market capitalization of $8.13M, reflecting its small size and early stage of development.
• Gross margin of 100.0%, indicating efficient management of the cost of goods sold, though this is typical for clinical-stage companies with limited product sales.
• Profit margin of -39662.8%, highlighting the significant R&D expenses and lack of revenue generation typical of clinical-stage biotech companies.
• Beta of 2.78, indicating high volatility relative to the market, reflecting the speculative nature of biotechnology stocks.
• Focus on Phase II trials for multiple indications, representing a critical stage in drug development with potential for significant value creation or loss.

Who Are JUNS's Competitors?

JUNS is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are JUNS's Key Strengths?

• Focus on neuro-inflammation, a growing area of research interest.
• Pipeline of multiple Phase II clinical trials.
• Resveratrol platform with potential for multiple applications.
• Orphan drug designations for certain pipeline candidates.

What Are JUNS's Weaknesses?

• Limited financial resources and small team.
• High dependence on clinical trial outcomes.
• Lack of commercialized products and revenue.
• High cash burn rate due to R&D expenses.

What Could Drive JUNS Stock Higher?

• Data readout from Phase II trial of JNS101 for Friedreich's Ataxia.
• Data readout from Phase II trial of JNS102 for mucopolysaccharidosis Type I.
• Enrollment and progress in Phase II trials for JNS107, JNS108, JNS109, JNS110, and JNS120.
• Potential for strategic partnerships or collaborations to accelerate drug development.
• Potential for securing additional funding through grants or equity offerings.

What Are the Key Risks for JUNS?

• Financial-distress signal — its Altman Z-Score of -20.81 sits in the distress zone (elevated bankruptcy risk).
• Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
• Failure to obtain positive results in ongoing Phase II clinical trials.
• Delays in clinical trial timelines due to regulatory hurdles or enrollment challenges.
• Competition from other companies developing treatments for the same indications.
• Dependence on securing additional funding to support research and development activities.
• Risk of patent challenges or intellectual property disputes.

What Are the Growth Opportunities for JUNS?

• Advancement of JNS101 for Friedreich's Ataxia: Successful completion of Phase II trials and subsequent FDA approval for JNS101 could represent a significant growth opportunity. Friedreich's Ataxia is a rare and debilitating disease with limited treatment options, creating a substantial unmet need. The market for Friedreich's Ataxia treatments is estimated to grow as awareness and diagnostic capabilities improve. Timeline for potential approval is estimated within the next 3-5 years, contingent on trial outcomes.
• Development of JNS102 for Mucopolysaccharidosis Type I: Similar to JNS101, the successful development of JNS102 for mucopolysaccharidosis Type I (MPS I) offers another significant growth avenue. MPS I is a rare genetic disorder with a high unmet need for effective therapies. Positive Phase II trial results could lead to accelerated development pathways and eventual market exclusivity. The market for MPS I treatments is projected to expand with advancements in gene therapy and enzyme replacement therapies. Anticipated timeline for potential approval is 3-5 years, pending clinical trial success.
• Expansion into Alzheimer's Disease Treatment with JNS108: The development of JNS108 for mild cognitive impairment and early Alzheimer's disease represents a substantial growth opportunity, given the large and growing prevalence of Alzheimer's. While the Alzheimer's disease treatment landscape is highly competitive, effective therapies for early-stage disease could capture a significant market share. Positive Phase II data could attract partnerships or further investment to accelerate development. The global Alzheimer's disease market is projected to reach billions of dollars in the coming years. Potential market entry could be 5-7 years, dependent on clinical trial outcomes.
• Leveraging Resveratrol Platform for New Indications: Jupiter Neurosciences' resveratrol platform offers the potential to develop treatments for a variety of other neuro-inflammatory conditions. This platform approach could lead to the identification of new drug candidates and expansion into additional therapeutic areas. The company could explore partnerships or collaborations to leverage its platform technology for broader applications. The market for neuro-inflammatory disease treatments is expanding as research uncovers the role of inflammation in various neurological disorders. This growth opportunity is ongoing and dependent on research and development efforts.
• Strategic Partnerships and Acquisitions: As a small, clinical-stage company, Jupiter Neurosciences could benefit from strategic partnerships or an acquisition by a larger pharmaceutical company. Such a transaction could provide access to additional funding, expertise, and resources to accelerate drug development and commercialization. The biotechnology industry is characterized by frequent mergers and acquisitions, with larger companies often acquiring smaller firms with promising drug candidates. This potential growth opportunity is contingent on the company's clinical trial progress and overall market conditions. The timeline is uncertain but could materialize within the next 2-3 years if clinical data is promising.

What Opportunities Does JUNS Have?

• Successful completion of Phase II trials and FDA approval for lead candidates.
• Strategic partnerships or acquisitions by larger pharmaceutical companies.
• Expansion into new therapeutic areas using resveratrol platform.
• Securing additional funding through grants or equity offerings.

What Threats Does JUNS Face?

• Clinical trial failures or delays.
• Regulatory hurdles and lengthy approval processes.
• Competition from other biotechnology and pharmaceutical companies.
• Patent challenges and intellectual property disputes.

What Are JUNS's Competitive Advantages?

• Proprietary resveratrol platform for developing neuro-inflammation treatments.
• Orphan drug designations for certain pipeline candidates, providing market exclusivity.
• Intellectual property protection for its drug candidates.
• First-mover advantage in developing specific treatments for rare diseases.

What Does JUNS Do?

Founded in 2016 and headquartered in Jupiter, Florida, Jupiter Neurosciences, Inc. is a clinical-stage research and development pharmaceutical company dedicated to developing treatments for neuro-inflammation. The company's core technology revolves around a resveratrol platform, which it leverages to create therapies for a range of neurological disorders. Jupiter Neurosciences was formerly known as Jupiter Orphan Therapeutics, Inc., changing its name in August 2021 to reflect its broader focus. The company's lead product candidates include JNS101, currently in Phase II trials for Friedreich's Ataxia, a debilitating genetic disease affecting the nervous system and mobility. Other key pipeline assets include JNS102, also in Phase II trials, targeting mucopolysaccharidosis Type I. Furthermore, the company is developing JNS107 for MELAS Syndrome, JNS108 for mild cognitive impairment and early Alzheimer's disease, JNS109 for amyotrophic lateral sclerosis (ALS), JNS110 for traumatic brain injury and concussion, and JNS120 for COVID-19 treatment. Jupiter Neurosciences operates with a small team, emphasizing a focused and agile approach to drug development within the competitive biotechnology sector.

What Products and Services Does JUNS Offer?

• Develop resveratrol-based treatments for neuro-inflammation.
• Conduct Phase II clinical trials for JNS101 targeting Friedreich's Ataxia.
• Conduct Phase II clinical trials for JNS102 targeting mucopolysaccharidosis Type I.
• Develop JNS107 for the treatment of MELAS Syndrome.
• Develop JNS108 for the treatment of mild cognitive impairment and early Alzheimer's disease.
• Develop JNS109 for amyotrophic lateral sclerosis (ALS).
• Develop JNS110 for traumatic brain injury and concussion.
• Develop JNS120 for COVID-19 treatment.

How Does JUNS Make Money?

• Focus on research and development of novel pharmaceutical products.
• Outsource manufacturing and clinical trial operations.
• Seek partnerships or licensing agreements for commercialization.
• Generate revenue through potential future product sales or milestone payments from partnerships.

What Industry Does JUNS Operate In?

Jupiter Neurosciences operates within the biotechnology industry, a sector characterized by high innovation, intense competition, and significant regulatory hurdles. The company focuses on neuro-inflammation, an area of growing research interest due to its role in various neurological disorders. The biotechnology industry is experiencing growth driven by advancements in genomics, personalized medicine, and increasing demand for novel therapies. Jupiter Neurosciences competes with other biotechnology and pharmaceutical companies developing treatments for neurological diseases, including both established players and smaller, specialized firms.

Who Are JUNS's Key Customers?

• Patients suffering from Friedreich's Ataxia.
• Patients suffering from mucopolysaccharidosis Type I.
• Patients suffering from MELAS Syndrome.
• Patients suffering from mild cognitive impairment and early Alzheimer's disease.

JUNS Valuation & Market Position

With a $8.13M market cap, Jupiter Neurosciences, Inc. sits in the micro-cap segment of the market. Relative to its peer group, JUNS's quantitative score of 21/100 is below the peer average of 87/100.

FY2026 estForward Outlook

Wall Street analysts project Jupiter Neurosciences, Inc. revenue of about $12.1M for fiscal 2026, with EPS near $0.06.

F-Score 3/9Financial Health

Jupiter Neurosciences, Inc.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -20.81 places it in the distress zone, a signal of elevated financial risk.

Key Financial Metrics

Its free cash flow yield is -76.4%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.51 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is -125.1%, the inverse of the P/E and a quick read on earnings relative to price.

JUNS Financials

JUNS Latest News

JUNS Analyst Consensus

JUNS MoonshotScore

Common Questions About JUNS (Healthcare)

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources